Ovarian Cancer Clinical Trial

Clinical Trial Finder Ovarian Cancer Trials

A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study

See Locations Near You

Summary

This was a multicenter, open-label extension study. Patients who received vismodegib (GDC-0449) in a Genentech-sponsored study and who had completed the parent study or who continued to receive vismodegib at the time the parent study closed were eligible for continued treatment in this protocol.

View Eligibility Criteria

Eligibility Criteria

This study only enrolled participants who took part in previous studies of vismodegib conducted by Genentech.

Inclusion Criteria:

Completed vismodegib treatment within 2-4 weeks in a Genentech-sponsored parent study or continued to receive vismodegib at the time the Genentech-sponsored parent study closed.
Expectation by the investigator that the participant may continue to benefit from additional vismodegib treatment.

Exclusion Criteria:

Intervening anti-tumor therapy not specified in the parent study (ie, non-protocol-specified chemotherapy, other targeted therapy, radiation therapy, or photodynamic therapy).

Study is for people with:

Ovarian Cancer

Phase:

Phase 2

Estimated Enrollment:

19

Study ID:

NCT00959647

Recruitment Status:

Completed

Sponsor:

Genentech, Inc.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 10 Locations for this study

See Locations Near You


Scottsdale Arizona, 85258, United States

Oakland California, 94609, United States

Palm Springs California, 92262, United States

Stanford California, 94305, United States

Baltimore Maryland, 21231, United States

Ann Arbor Michigan, 48109, United States

Detroit Michigan, 48201, United States

Las Vegas Nevada, 89106, United States

Cincinnati Ohio, 45242, United States

Houston Texas, 77030, United States
Load More

How clear is this clinincal trial information?

Study is for people with:

Ovarian Cancer

Phase:

Phase 2

Estimated Enrollment:

19

Study ID:

NCT00959647

Recruitment Status:

Completed

Sponsor:


Genentech, Inc.

How clear is this clinincal trial information?

Clinical Trial Resources

Why I’d Choose a Clinical Trial For Myself
Clinical Trials Can be Life-Saving for Some
Promising Immunotherapy Trials for Ovarian Cancer
×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider